Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1819479 in Healthy Females
NCT05440799Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BI 1819479 with Placebo (2 arms). Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator up to 106 days. Started Jul 2022; status: completed.
02
Drugs
BI1819479
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05440799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440799.